Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE), 2025
ESPE-ESE 2025 10 - 13 May 2025

Long-term efficacy and safety of once-weekly somapacitan in children with growth hormone deficiency: 7-year results from the randomised REAL 3 trial

Authors :

Lars Sävendahl1; Tadej Battelino2; Michael Højby3; Tina Leunbach3; Paul Saenger4; Lawrence Silverman5; Reiko Horikawa6
Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Keywords
Rare Endocrine Disorder
Congress oral presentation
Somapacitan